Author

Kirk E. Hevener

University of Tennessee Health Science CenterORCID 0000-0002-5584-3625Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:C. elegans· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:metagenomics· 1 Organism:mouse· 1

Frequent Co-Authors

Chetna DurejaiD· 1 shared Dianqing SuniD· 1 shared Fahad Bin Aziz Pavel· 1 shared Isaac PrahiD· 1 shared Jacob T. RutherfordiD· 1 shared Julian Gregston HurdleiD· 1 shared Krissada NorseedaiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

Chetna DurejaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MicrobiologyAntimicrobial Agents and ChemotherapyPeer-reviewedJan 24, 2024

In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy

Chetna Dureja, Jacob T. Rutherford, Fahad Bin Aziz Pavel…·Julian Gregston Hurdle

This study evaluates the in vivo efficacy of phenylimidazole 296 against C. difficile by targeting CdFabK, showing it retains microbiome stability better than vancomycin and fidaxomicin.

5 citations

C. elegansmouse

𝕏 PostBluesky